Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Nurix Therapeutics seeks a Director of Drug Safety to lead medical safety strategy for its clinical programs, guiding safety reviews and benefit–risk assessments across the development pipeline. The role emphasizes aggregate safety analyses, regulatory interactions, and proactive risk management.
You will collaborate with clinical development, regulatory affairs, medical affairs, and safety operations to shape global safety strategy, respond to authorities, and support inspections.
Join Nurix’s pharmacovigilance team to help ensure patient safety across our clinical pipeline of targeted protein degradation therapies. As Director, Drug Safety, you’ll lead aggregate safety analysis, benefit–risk assessments, and safety strategy for assigned programs — shaping how we evaluate risk and bring new medicines safely to patients. It’s a chance to influence critical safety decisions at the intersection of clinical medicine, data, and drug development.
Salary Range: Non-MD $247,300 - $280,400 | MD $295,000 - $317,100
The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.
Location: Onsite – Brisbane, CA
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI‑integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader‑based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.